How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/non-radiographic-axial-spondyloarthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non-Radiographic Axial Spondyloarthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Radiographic Axial Spondyloarthritis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-Radiographic Axial Spondyloarthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Kyntheum	BRODALUMAB	Valeant Luxembourg	Interleukin-17 Receptor A Antagonist [EPC]	Interleukin-17 receptor	2017-01-01
Taltz	ixekizumab	Eli Lilly	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Taltz	Taltz	Yale University		Interleukin-17A
TNF Inhibitor	tnf-inhibitor	Pfizer	Monoclonal Antibody	TNF-alpha
tumor necrosis factor inhibitors (TNFi)	tumor-necrosis-factor-inhibitors-tnfi	Pfizer	biologic	tumor necrosis factor
Cosentyx	Cosentyx	Janssen Research & Development, LLC		Interleukin-17A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Non-Radiographic Axial Spondyloarthritis
Eli Lilly · 1 drug in Non-Radiographic Axial Spondyloarthritis
Janssen Research & Development, LLC · 1 drug in Non-Radiographic Axial Spondyloarthritis
Novartis · 1 drug in Non-Radiographic Axial Spondyloarthritis
Valeant Luxembourg · 1 drug in Non-Radiographic Axial Spondyloarthritis
Yale University · 1 drug in Non-Radiographic Axial Spondyloarthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-Radiographic Axial Spondyloarthritis:

Cite this brief

Drug Landscape (2026). Non-Radiographic Axial Spondyloarthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-radiographic-axial-spondyloarthritis. Accessed 2026-06-10.

Non-Radiographic Axial Spondyloarthritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing